Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Current Taxes Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Burning Rock Biotech (BNR) Preferred Stock Liabilities (2019)

Burning Rock Biotech has reported Preferred Stock Liabilities over the past 1 years, most recently at $216.7 million for Q4 2019.

For Q4 2019, Preferred Stock Liabilities changed N/A year-over-year to $216.7 million; the TTM value through Dec 2019 reached $216.7 million, changed N/A, while the annual FY2019 figure was $221.2 million, N/A changed from the prior year.
Preferred Stock Liabilities for Q4 2019 was $216.7 million at Burning Rock Biotech.
Over five years, Preferred Stock Liabilities peaked at $216.7 million in Q4 2019 and troughed at $216.7 million in Q4 2019.